Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron

Nicole DeFeudis

Editor

Vaccibody who? A little over a year after securing a $700 million-plus deal with Roche for its neoantigen cancer vaccine, the Norwegian biotech has attracted yet another Big Pharma partner with deep pockets — and with it, a new name and facelift.

Regeneron is betting nearly $1 billion on five new vaccine programs from Vaccibody, now called Nykode Therapeutics. The deal will double Nykode’s current pipeline, adding three programs in cancer and two in infectious disease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force

Vac­ci­body gets a new name and loads up with near­ly $1B in biobucks for new vac­cine pact with Re­gen­eron

Nicole DeFeudis

Editor

Unlock this article instantly by becoming a free subscriber.

more like this

J&J's AI head jumps to Re­cur­sion; Doug Williams re­signs as Sana's R&D chief

Rare neu­ro dis­or­der of­fers new area for com­pe­ti­tion, an­a­lysts say: #AAN24

Ver­tex, Alpine’s IgAN drug has Hu­mi­ra-like po­ten­tial. But not all in­di­ca­tions are cre­at­ed equal

CSL Vi­for pro­pos­es a mar­ket­ing cam­paign to set­tle Eu­ro­pean Com­mis­sion in­ves­ti­ga­tion

Take­da wins la­bel ex­pan­sion for sub­cu­ta­neous En­tyvio, cre­at­ing 'flex­i­bil­i­ty' for Crohn's pa­tients

Sanofi re­struc­tures US com­mer­cial vac­cines sales force

Vaccibody gets a new name and loads up with nearly $1B in biobucks for new vaccine pact with Regeneron

J&J's AI head jumps to Recursion; Doug Williams resigns as Sana's R&D chief

Rare neuro disorder offers new area for competition, analysts say: #AAN24

Vertex, Alpine’s IgAN drug has Humira-like potential. But not all indications are created equal

CSL Vifor proposes a marketing campaign to settle European Commission investigation

Takeda wins label expansion for subcutaneous Entyvio, creating 'flexibility' for Crohn's patients

Sanofi restructures US commercial vaccines sales force